More about
Brexucabtagene Autoleucel
News
April 05, 2021
2 min read
Save
Kite submits supplemental BLA for Tecartus to treat advanced ALL
Kite Pharma submitted a supplemental biologics license application to the FDA for brexucabtagene autoleucel to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, according to the agent’s manufacturer.
News
August 14, 2020
4 min read
Save
FDA approval of CAR-T for mantle cell lymphoma could be ‘practice changing’
The FDA approval of brexucabtagene autoleucel represents a major step forward for the treatment of adults with relapsed or refractory mantle cell lymphoma, experts told Healio.
News
July 24, 2020
2 min read
Save
FDA approves Tecartus, first CAR T-cell therapy for mantle cell lymphoma
The FDA granted accelerated approval to brexucabtagene autoleucel for treatment of adults with relapsed or refractory mantle cell lymphoma.